Pre-clinical data also showed that blockade of CD96 alone or in combination with anti-PD-1 or anti-CTLA-4 or doxorubicin promotes NK cell activity (in terms of IFN-γ release) and a better control of tumor progression (45, 46). This evidence concerns the gene CTLA4 and neoplasm.